A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations

Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab

Sponsors: 7 Hills Pharma, LLC

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 14, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments